Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
Centessa Pharmaceuticals (Nasdaq: CNTA) announced its upcoming addition to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes companies classified as Biotech or Pharma that meet specified criteria. The announcement reflects Centessa's innovative, asset-centric model aimed at developing impactful medicines across multiple therapeutic areas such as oncology and immunology. This addition may enhance Centessa's visibility and investor interest, potentially influencing its stock performance positively.
- Inclusion in the NASDAQ Biotechnology Index may increase visibility and credibility among investors.
- The asset-centric model allows for focused development across diverse therapeutic areas.
- None.
BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 20, 2021.
The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. More information about the Index can be found at https://indexes.nasdaqomx.com/index/overview/NBI.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa’s asset-centric companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. For more information, visit www.centessa.com.
Contacts:
Investors:
Jennifer Porcelli, Head of Investor Relations
Centessa Pharmaceuticals
jennifer.porcelli@centessa.com
Media:
Dan Budwick, 1AB
dan@1abmedia.com
